[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR057636A2 - Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria - Google Patents

Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria

Info

Publication number
AR057636A2
AR057636A2 ARP070100583A ARP070100583A AR057636A2 AR 057636 A2 AR057636 A2 AR 057636A2 AR P070100583 A ARP070100583 A AR P070100583A AR P070100583 A ARP070100583 A AR P070100583A AR 057636 A2 AR057636 A2 AR 057636A2
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition containing
ibandronate
prepare
procedure
Prior art date
Application number
ARP070100583A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057636A2 publication Critical patent/AR057636A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procedimiento para preparar una composicion farmacéutica que contiene ibandronato en forma de dosificacion unitaria, conteniendo dicha composicion hasta 50 mg. de ibandronato por dosis unitaria, que comprende granular el ibandronato en presencia de agua en un granulador de lecho fluidificado con adyuvantes para formar un granulado; secar el granulado en el granulador de lecho fluidificado; y procesar el granulado para producir la composicion farmacéutica en forma de dosificacion unitaria, en donde los adyuvantes comprenden lactosa en una cantidad de aproximadamente 25 a aproximadamente 75% en peso de la composicion, celulosa microcristalina en una cantidad de aproximadamente 10 a aproximadamente 20% en peso de la composicion, y polivinil pirrolidona en una cantidad de aproximadamente 2 a aproximadamente 3% en peso de la composicion.
ARP070100583A 1998-10-09 2007-02-12 Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria AR057636A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119103A EP0998933A1 (de) 1998-10-09 1998-10-09 Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation

Publications (1)

Publication Number Publication Date
AR057636A2 true AR057636A2 (es) 2007-12-12

Family

ID=8232770

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105082A AR019242A1 (es) 1998-10-09 1999-10-07 Procedimiento para composiciones farmaceuticas por via oral
ARP070100583A AR057636A2 (es) 1998-10-09 2007-02-12 Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990105082A AR019242A1 (es) 1998-10-09 1999-10-07 Procedimiento para composiciones farmaceuticas por via oral

Country Status (16)

Country Link
US (1) US6419955B1 (es)
EP (2) EP0998933A1 (es)
JP (1) JP3725427B2 (es)
KR (1) KR100496086B1 (es)
CN (1) CN1154498C (es)
AR (2) AR019242A1 (es)
AT (1) ATE314075T1 (es)
AU (1) AU744142B2 (es)
BR (1) BR9914368A (es)
CA (1) CA2345818C (es)
DE (1) DE69929219T2 (es)
DK (1) DK1117411T3 (es)
ES (1) ES2255301T3 (es)
TR (1) TR200100888T2 (es)
WO (1) WO2000021541A1 (es)
ZA (1) ZA200102273B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
CN100551377C (zh) * 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
PL212072B1 (pl) † 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
JP4601271B2 (ja) * 2003-08-01 2010-12-22 大洋薬品工業株式会社 圧縮成形製剤およびその製造方法
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
JP4559431B2 (ja) * 2004-08-23 2010-10-06 テバ ファーマシューティカル インダストリーズ リミティド 固体及び結晶イバンドロネートナトリウム及びその調製方法
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
RU2009110253A (ru) * 2006-08-24 2010-09-27 БЁРИНГЕР ИНГЕЛЬХАЙМ ФАРМА ГМБХ УНД Ко. КГ (DE) Способ приготовления таблеток прамипексолдигидрохлорида, обладающих высокой стабильностью при хранении
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20100247737A1 (en) * 2007-11-27 2010-09-30 Hiroshi Sakamoto Method for producing granulated preparation
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
NO2459176T3 (es) 2009-07-31 2018-02-24
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
EP2661262B1 (en) 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
CN103110515A (zh) * 2012-11-14 2013-05-22 江苏江山制药有限公司 氨基葡萄糖硫酸钾盐颗粒的生产方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EP3376308B1 (fr) * 2017-03-17 2019-11-13 Montres Jaquet Droz SA Mécanisme de remontage d'une pièce d'horlogerie
CN112972400A (zh) * 2021-03-09 2021-06-18 华侨大学 可快速崩解的米诺膦酸颗粒及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
ES2040733T3 (es) * 1986-12-20 1993-11-01 Boehringer Mannheim Gmbh Medicamentos que contienen clodronato y procedimiento para su preparacion.
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
AU661080B2 (en) * 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
EP0583470A4 (en) * 1992-01-10 1995-07-26 Obschestvo S Ogranichennoy Otv PHARMACEUTICAL COMPOSITION IN GRANULATE FORM AND PRODUCTION METHOD.
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
US5656288A (en) 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions

Also Published As

Publication number Publication date
CN1319016A (zh) 2001-10-24
EP1117411A1 (en) 2001-07-25
EP1117411B1 (en) 2005-12-28
CN1154498C (zh) 2004-06-23
AU744142B2 (en) 2002-02-14
JP3725427B2 (ja) 2005-12-14
DE69929219D1 (de) 2006-02-02
AR019242A1 (es) 2001-12-26
ATE314075T1 (de) 2006-01-15
CA2345818C (en) 2006-01-03
TR200100888T2 (tr) 2001-07-23
ZA200102273B (en) 2002-06-19
WO2000021541A1 (en) 2000-04-20
DE69929219T2 (de) 2006-08-17
EP0998933A1 (de) 2000-05-10
JP2002527399A (ja) 2002-08-27
ES2255301T3 (es) 2006-06-16
AU6199099A (en) 2000-05-01
US6419955B1 (en) 2002-07-16
KR20010073202A (ko) 2001-07-31
KR100496086B1 (ko) 2005-06-20
BR9914368A (pt) 2001-08-07
DK1117411T3 (da) 2006-04-24
CA2345818A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AR057636A2 (es) Procedimiento para preparar una composicion farmaceutica que contiene ibandronato en forma de dosificacion unitaria
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
NO20053106L (no) Oral, analgesisk doseringsform med forlenget frigivelse.
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
ID28735A (id) Sediaan farmasi pelepasan terkendali satuan ganda yang bebas dan proses pembuatennya
DK1246622T3 (da) Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse
DE69209323D1 (de) Mehrschichttabletten mit gesteuerter wirkstoffabgabe enthaltend sowohl naproxen als auch naproxen natriumsalz
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
BR0307331A (pt) Formulações granuladas a seco de azitromicina
AR036813A1 (es) Composiciones farmaceuticas
AR021443A1 (es) Formulacion de liberacion controlada de divalproex sodio
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
AP2003002763A0 (en) Controlled release formulations for oral administration
ES2175073T3 (es) Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua.
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
SE8901003L (sv) Snabbloesliga preparat
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
FI933975A0 (fi) Tabletter som kontrollerat avgiver naproxen
AR004196A1 (es) Un metodo a alta velocidad para preparar granulos esfericos que comprende un medicamento para uso farmaceutico, granulos obtenibles mediante este metodoy una bolsita que contiene dichos granulos
CO5271706A1 (es) Unidad de dosis de mirtazapina para el tratamiento de transtornos del sueno
FI913409A0 (fi) Menetelmä vaikuttavana aineena mesnaa sisältävien tablettien ja granulaatin valmistamiseksi
ES2125198B1 (es) Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Legal Events

Date Code Title Description
FC Refusal